Minister of Industry and Technology Mustafa Varank stated that they aim to produce the vaccine developed by Turkey with their own local and national technologies before the end of the year and said, “If we can find enough volunteers in the phase studies of our vaccine candidates and if the results of our vaccine candidates are successful, before the end of the year, Turkey's domestic and national We believe we can obtain the vaccine. " said. Minister Varank, regarding the adenovirus-based vaccine candidate, said: “Our Adenovirus-based vaccine has of course differences from other vaccines in this technology in the world. Our teacher's vaccine is a vaccine designed to include all 4 proteins of the virus. Therefore, we think it will be more effective. " made its evaluation.
Minister Varank paid a festive visit to Ankara City Hospital Clinical Research Center and Ankara University Cancer Research Institute, where domestic vaccine development studies against Kovid 19 continue.
TÜBİTAK President Prof. Dr. Hasan Mandal and TÜBİTAK Marmara Research Center Genetic Engineering and Biotechnology Institute Director Prof. Dr. During the visit accompanied by Şaban Tekin, Minister Varank offered baklava to scientists and researchers who participated in local vaccination studies.
The first stop of Minister Varank's holiday visits was Ankara City Hospital Clinical Research Center. Varank, Professor of Konya Selcuk University. Dr. He received information about the local inactivated vaccine candidate, which was developed by Osman Erganiş and his team and passed to Phase 1.
Minister Varank, in his statement after his visit, celebrated the Ramadan Feast of all Turkey, especially the healthcare personnel working for the peace and welfare of the country, the security forces and the laborers who shed sweat despite the holiday. Pointing out that there was a bitter holiday due to the Kovid-19 outbreak and recent events in Palestine, Varank said:
DOMESTIC VACCINE STUDIES
One of the most important pillars of vaccine development studies is human trials. A team in Kayseri is waiting to move on to Phase 3 in the inactive vaccine study. We are planning to move on to Phase 2 in the VLP vaccine. Here, too, if the Phase 1 studies of our teacher Osman Erganiş end in the inactive vaccine candidate until the middle of June, we will test the vaccines developed by our own scientists with our own technologies and produced in GMP standards in our production facilities in Turkey.
PRODUCTION CAPACITY CAN BE INCREASED QUICKLY
These vaccines are produced at world standards and hit on volunteers. About the inactive vaccine, our teacher Osman is working with Vetal, a private sector company in Adıyaman. If this inactive vaccine candidate completes Phase 3 and is successful, it will be produced in Vetal. Pilot production of our VLP vaccine was realized in Nobel company. If the VLP vaccine is successful, it will be produced in Nobel in Kocaeli. These private sector companies are already powerful companies that have investments in this field. Since they also get GMP certificates, they will be able to produce these vaccines in high doses and deliver them to our people very easily.
SECOND STOP ANKARA UNIVERSITY
The second stop within the scope of Minister Varank's holiday visit was Ankara University Cancer Research Institute, where adenovirus-based vaccination studies were carried out. Rector Prof. Dr. Necdet Ünüvar and Institute Director Prof. Dr. Receiving information from Hakan Akbulut on the adenovirus-based vaccine candidate developed against Kovid-19, Varank said that this vaccine candidate has similar technology to Sputnik V and AstraZeneca vaccines. Minister Varank underlined that Hakan Hoca also made a great effort and said:
WE THINK IT WILL BE MORE EFFECTIVE
I asked him how long he stayed in Tekirdağ at the facility where the pilot production of this vaccine was made, and he said that he actually worked there for 95 days. Of course, our adenovirus-based vaccine has differences from other vaccines in this technology in the world. Our teacher's vaccine is a vaccine designed to include all 4 proteins of the virus. Therefore, we think it will be more effective. We know that our teacher prefers a virus that is less harmful or will not harm human beings and has a more advantageous advantage compared to other adenoviruses used in the world.
APPLICATION HAS BEEN MADE TO TITCK
Mentioning that the pilot production of the vaccine candidate in question was carried out under GMP conditions, Varank said, “Our teacher made an application to the Turkish Medicines and Medical Devices Agency (TITCK). We expect a conclusion from TITCK next week about the start of human trials of this vaccine. If the result comes out, we will be at the stage of human trials in 2 inactive, 1 VLP and 1 adenovirus-based vaccine candidates in Turkey. We believe that if we can find enough volunteers in the phase studies of our vaccine candidates and the results of our vaccine candidates are successful, we will be able to obtain Turkey's domestic and national vaccine before the end of the year, just like the autumn.
THEY SHOW GREAT FAILURE
Our teachers under the platform are in their laboratories and production facilities today. As long as Turkey can produce its own vaccine, they make great efforts to achieve success that can heal both Turkey and humanity.
TRANSPARENT AND SCIENTIFIC
We think that it will not be a problem to find volunteers in future clinical trials of vaccines. We take these processes “very transparent and scientific. All of our professors report their work to the world, they publish their work on their websites, we have contact with the World Health Organization about our work, we inform them. As a result of these efforts and thanks to our volunteers, we believe that we will improve our vaccine.